SEC Company Response from IDENIX PHARMACEUTICALS INC (CIK 0001093649) — Sep 9, 2005

IDENIX PHARMACEUTICALS INC (CIK 0001093649)
Date: Sept. 9, 2005 · CIK: 0001093649 · Accession: 0000950135-05-005320

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-127710

Date

September 9, 2005

Author

Not clearly detected

Form

CORRESP

Company

IDENIX PHARMACEUTICALS INC (CIK 0001093649)

Letter

Re: Idenix Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-127710 Request for Acceleration ------------------------

<PAGE>

IDENIX PHARMACEUTICALS, INC. 60 Hampshire Street Cambridge, MA 02139

September 9, 2005

VIA EDGAR AND FACSIMILE (202-772-9217) Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Attn: Gregory S. Belliston, Esq.

Mr. Belliston:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Idenix Pharmaceuticals, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-127710) (the "Registration Statement") so that it may become effective at 4:00 p.m. on Tuesday, September 13, 2005, or as soon thereafter as practicable.

The Registrant hereby acknowledges that:

(i) should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

(iii) the Registrant may not assert the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you require additional information, please do not hesitate to contact Susan W. Murley at (617) 526-6832 or Eric C. Burnett at (617) 526-6523 of Wilmer Cutler Pickering Hale and Dorr LLP.

Very truly yours,
IDENIX PHARMACEUTICALS, INC.

Show Raw Text

<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
<PAGE>

                          IDENIX PHARMACEUTICALS, INC.
                               60 Hampshire Street
                               Cambridge, MA 02139

                                September 9, 2005

VIA EDGAR AND FACSIMILE (202-772-9217)
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Gregory S. Belliston, Esq.

         Re:      Idenix Pharmaceuticals, Inc.
                  Registration Statement on Form S-3
                  File No. 333-127710
                  Request for Acceleration
                  ------------------------

Mr. Belliston:

       Pursuant to Rule 461 promulgated under the Securities Act of 1933, as
amended, Idenix Pharmaceuticals, Inc. (the "Registrant") hereby requests
acceleration of the effective date of its Registration Statement on Form S-3
(File No. 333-127710) (the "Registration Statement") so that it may become
effective at 4:00 p.m. on Tuesday, September 13, 2005, or as soon thereafter as
practicable.

       The Registrant hereby acknowledges that:

       (i)    should the Securities and Exchange Commission (the "Commission")
              or the staff, acting pursuant to delegated authority, declare the
              Registration Statement effective, it does not foreclose the
              Commission from taking any action with respect to the Registration
              Statement;

       (ii)   the action of the Commission or the staff, acting pursuant to
              delegated authority, in declaring the Registration Statement
              effective, does not relieve the Registrant from its full
              responsibility for the adequacy and accuracy of the disclosure in
              the Registration Statement; and

       (iii)  the Registrant may not assert the action of the Commission or the
              staff, acting pursuant to delegated authority, in declaring the
              Registration Statement effective as a defense in any proceeding
              initiated by the Commission or any person under the federal
              securities laws of the United States.

       If you require additional information, please do not hesitate to contact
Susan W. Murley at (617) 526-6832 or Eric C. Burnett at (617) 526-6523 of Wilmer
Cutler Pickering Hale and Dorr LLP.

                              Very truly yours,

                              IDENIX PHARMACEUTICALS, INC.

                              By: /s/ Andrea J. Corcoran
                                  ---------------------------------------------
                                  Name: Andrea J. Corcoran
                                  Title: Executive Vice President,
                                          Legal and Administration and Secretary

</TEXT>
</DOCUMENT>

SecProbe.io